Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK-001 trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza ...
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...
The phase 3 KEYLYNK-001 trial has been evaluating Merck’s anti-PD-1 therapy Keytruda in combination with chemotherapy followed by maintenance with the company’s AstraZeneca-partnered PARP inhibitor ...
A few days ago, Merck lent evidence to that conjecture with a readout from the phase 3 KEYLYNK-001 trial in first-line ovarian cancer. There, Keytruda’s addition to Lynparza maintenance—plus ...
Recently, Merck announced topline data from the Phase 3 KEYLYNK-001 trial of Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza, with or without bevacizumab ...
Recently, Merck announced topline data from the Phase 3 KEYLYNK-001 trial of Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza, with or without bevacizumab, as a ...
Earlier this month, MRK announced that its Phase 3 trial of the drug KEYLYNK-001 had been successful in patients with advanced epithelial ovarian cancer. The company is making significant progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback